Mefloquine and psychotomimetics share neurotransmitter receptor and transporter interactions in vitro
- First Online:
- 401 Downloads
Mefloquine is used for the prevention and treatment of chloroquine-resistant malaria, but its use is associated with nightmares, hallucinations, and exacerbation of symptoms of post-traumatic stress disorder. We hypothesized that potential mechanisms of action for the adverse psychotropic effects of mefloquine resemble those of other known psychotomimetics.
Using in vitro radioligand binding and functional assays, we examined the interaction of (+)- and (−)-mefloquine enantiomers, the non-psychotomimetic anti-malarial agent, chloroquine, and several hallucinogens and psychostimulants with recombinant human neurotransmitter receptors and transporters.
Hallucinogens and mefloquine bound stereoselectively and with relatively high affinity (Ki = 0.71–341 nM) to serotonin (5-HT) 2A but not 5-HT1A or 5-HT2C receptors. Mefloquine but not chloroquine was a partial 5-HT2A agonist and a full 5-HT2C agonist, stimulating inositol phosphate accumulation, with similar potency and efficacy as the hallucinogen dimethyltryptamine (DMT). 5-HT receptor antagonists blocked mefloquine’s effects. Mefloquine had low or no affinity for dopamine D1, D2, D3, and D4.4 receptors, or dopamine and norepinephrine transporters. However, mefloquine was a very low potency antagonist at the D3 receptor and mefloquine but not chloroquine or hallucinogens blocked [3H]5-HT uptake by the 5-HT transporter.
Mefloquine, but not chloroquine, shares an in vitro receptor interaction profile with some hallucinogens and this neurochemistry may be relevant to the adverse neuropsychiatric effects associated with mefloquine use by a small percentage of patients. Additionally, evaluating interactions with this panel of receptors and transporters may be useful for characterizing effects of other psychotropic drugs and for avoiding psychotomimetic effects for new pharmacotherapies, including antimalarial quinolines.
KeywordsMefloquine Chloroquine Quinine Malaria LSD Psychotomimetic Neurotransmitter Transporter Serotonin receptor Dopamine receptor
- Dow GS, Milner E, Bathurst I, Bhonsle J, Caridha D, Gardner S, Gerena L, Kozar M, Lanteri C, Mannila A, McCalmont W, Moon J, Read KD, Norval S, Roncal N, Shackleford DM, Sousa J, Steuten J, White KL, Zeng Q, Charman SA (2011) Central nervous system exposure of next generation quinoline methanols is reduced relative to mefloquine after intravenous dosing in mice. Malar J 10:150PubMedCentralPubMedCrossRefGoogle Scholar
- Dzierszinski F, Coppin A, Mortuaire M, Dewailly E, Slomianny C, Ameisen JC, DeBels F, Tomavo S (2002) Ligands of the peripheral benzodiazepine receptor are potent inhibitors of Plasmodium falciparum and Toxoplasma gondii in vitro. Antimicrob Agents Chemother 46(10):3197–3207PubMedCentralPubMedCrossRefGoogle Scholar
- Gazi L, Bobirnac I, Danzeisen M, Schüpbach E, Langenegger D, Sommer B, Hoyer D, Tricklebank M, Schoeffter P (1999) Receptor density as a factor governing the efficacy of the dopamine D4 receptor ligands, L-745,870 and U-101958 at human recombinant D4.4 receptors expressed in CHO cells. Br J Pharmacol 128(3):613–620PubMedCentralPubMedCrossRefGoogle Scholar
- Gillespie RJ, Adams DR, Bebbington D, Benwell K, Cliffe IA, Dawson CE, Dourish CT, Fletcher A, Gaur S, Giles PR, Jordan AM, Knight AR, Knutsen LJ, Lawrence A, Lerpiniere J, Misra A, Porter RH, Pratt RM, Shepherd R, Upton R, Ward SE, Weiss SM, Williamson DS (2008) Antagonists of the human adenosine A2A receptor: Part 1. Discovery and synthesis of thieno[3,2-d]pyrimidine-4-methanone derivatives. Bioorg Med Chem Lett 18(9):2916–2919PubMedCrossRefGoogle Scholar
- Haynes RK, Cheu KW, Chan HW, Wong HN, Li KY, Tang MM, Chen MJ, Guo ZF, Guo ZH, Sinniah K, Witte AB, Coghi P, Monti D (2012) Interactions between artemisinins and other antimalarial drugs in relation to the cofactor model—a unifying proposal for drug action. Chem Med Chem 7(12):2204–2226PubMedCrossRefGoogle Scholar
- Iglesias R, Locovei S, Roque A, Alberto AP, Dahl G, Spray DC, Scemes E. (2008) P2X7 receptor-Pannexin1 complex: pharmacology and signaling. Am J Physiol Cell Physiol 295:C752–60Google Scholar
- Kennedy K (2009) Army scales back use of anti-malaria drug. Army Times, March 24:2009Google Scholar
- Knight AR, Misra A, Quirk K, Benwell K, Revell D, Kennett G, Bickerdike M (2004) Pharmacological characterisation of the agonist radioligand binding site of 5HT(2A), 5HT(2B) and 5HT(2C) receptors. Naunyn-Schmeideberg’s Arch Pharmacol 370:114–123Google Scholar
- MacLean D.S. (2013) Crazy Pills. The New York Times. August 7. Available at http://www.nytimes.com/2013/08/08/opinion/crazy-pills.html?_r=0
- Nichols DE (2004) Hallucinogens. Pharmacol Ther 101:131–181Google Scholar
- Nichols DE, Frescas S, Marona-Lewicka D, Kurrasch-Orbaugh DM. (2002) Lysergamides of isomeric 2,4-dimethylazetidines map the binding orientation of the diethylamide moiety in the potent hallucinogenic agent N,N-diethyllysergamide (LSD). J Med Chem 45(19):4344–4349Google Scholar
- Schlagenhauf P, Adamcova M, Regep L, Schaerer MT, Bansod S, Rhein HG. (2011) Use of mefloquine in children- a review of dosage, pharmacokinetics and tolerability data. Malar J 10:292–302Google Scholar
- Toll L, Berzetei-Gurske IP, Polgar WE, Brandt SR, Adapa ID, Rodriguez L, Schwartz RW, Haggart D, O'Brien A, White A, Kennedy JM, Craymer K, Farrington L, Auh JS (1998) Standard binding and functional assays related to medications development division testing for potential cocaine and opiate narcotic treatment medications. NIDA Res Monogr 178:440–466PubMedGoogle Scholar
- Wang Y, Denisova JV, Kang KS, Fontes JD, Zhu BT, Belousov AB. (2010) Neuronal gap junctions are required for NMDA receptor-mediated excitotoxicity: implications in ischemic stroke. J Neurophysiol 104(6):3551–3556.Google Scholar